Search research articles
Contact Us
Filters
Showing results (221-230 of 253) with videos related to
Page
of 26
Sort By:
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
European Urology
|
January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study
Daniel W Lin, Mei-Chiung Shih, William Aronson, et al.
Urology
|
September 17, 2002
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
Peter R Carroll, Philip W Kantoff, Steven P Balk, et al.
Journal of the National Cancer Institute
|
May 18, 2023
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study
Ryan W Huey, Aakash Tushar Shah, Honey V Reddi, et al.
JNCI Cancer Spectrum
|
May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study
Emmanuel S Antonarakis, Qing Cao, Victoria Catharine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
Elizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 253) with videos related to
Sort By:
Page
of 26
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
European Urology
|
January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study
Daniel W Lin, Mei-Chiung Shih, William Aronson, et al.
Urology
|
September 17, 2002
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
Peter R Carroll, Philip W Kantoff, Steven P Balk, et al.
Journal of the National Cancer Institute
|
May 18, 2023
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study
Ryan W Huey, Aakash Tushar Shah, Honey V Reddi, et al.
JNCI Cancer Spectrum
|
May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study
Emmanuel S Antonarakis, Qing Cao, Victoria Catharine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
Elizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
Page
of 26